Acceleron Pharma SVP Sells $74,050 in Stock (XLRN)
Acceleron Pharma (NASDAQ:XLRN) SVP Matthew L. Sherman sold 2,500 shares of Acceleron Pharma stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $29.62, for a total value of $74,050.00. Following the transaction, the senior vice president now directly owns 27,858 shares in the company, valued at approximately $825,154. The sale was disclosed in a document filed with the SEC, which is available at this link.
Acceleron Pharma (NASDAQ:XLRN) opened at 27.71 on Thursday. Acceleron Pharma has a 1-year low of $16.78 and a 1-year high of $57.89. The stock has a 50-day moving average of $29.15 and a 200-day moving average of $35.46. The company’s market cap is $881.1 million.
Acceleron Pharma (NASDAQ:XLRN) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.01. Analysts expect that Acceleron Pharma will post $-1.44 EPS for the current fiscal year.
A number of research firms have recently commented on XLRN. Analysts at Leerink Swann initiated coverage on shares of Acceleron Pharma in a research note on Thursday, August 14th. They set an “outperform” rating and a $57.00 price target on the stock. Analysts at FBR Capital Markets initiated coverage on shares of Acceleron Pharma in a research note on Wednesday, August 13th. They set an “outperform” rating and a $47.00 price target on the stock. Four investment analysts have rated the stock with a buy rating, Acceleron Pharma presently has an average rating of “Buy” and an average target price of $51.00.
Acceleron Pharma Inc is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of protein therapeutics for cancer and rare diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.